Flora Tassone

Dr. Flora Tassone

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
FTFlora Tassone
Flora Tassone
RPRuiqin Pan
Ruiqin Pan
KAkhaled Amiri
khaled Amiri
ATAnnette K. Taylor
Annette K. Taylor
PHPaul J. Hagerman
Paul J. Hagerman

21 December 2012 in Genome Medicine
Verified
Journal Article
Open access
PDF file
FTFlora Tassone
Flora Tassone
KIKa Pou Iong
Ka Pou Iong
TTTzu-Han Tong
Tzu-Han Tong
JLJoyce Lo
Joyce Lo
LGLouise W Gane
Louise W Gane
RHRandi J Hagerman
Randi J Hagerman
Background: Population screening for FMR1 mutations has been a topic of considerable discussion since the FMR1 gene was identified in 1991. Advances in understanding the molecular basis of fragile X syndrome (FXS) and in genetic testing methods have led to new, less expensive methodology to use for large screening endeavors. A core criterion for newborn screening is an accurate understanding of the public health burden of a disease, considering both disease severity and prevalence rate. This article addresses this need by reporting prevalence rates observed in a pilot newborn screening study for FXS in the US. Methods: Blood spot screening of 14,207 newborns (7,312 males and 6,895 females) was conducted in three birthing hospitals across the United States beginning in November 2008, using a PCR-based approach. Results: The prevalence of gray zone alleles was 1:66 females and 1:112 males, while the prevalence of a premutation was 1:209 females and 1:430 males. Differences in prevalence rates were observed among the various ethnic groups; specifically higher frequency for gray zone alleles in males was observed in the White group compared to the Hispanic and African-American groups. One full mutation male was identified (>200 CGG repeats). Conclusions: The presented pilot study shows that newborn screening in fragile X is technically feasible and provides overall prevalence of the premutation and gray zone alleles in the USA, suggesting that the prevalence of the premutation, particularly in males, is higher than has been previously reported.

23 January 2012 in Genes, Brain and Behavior
Verified
Journal Article
Open access
PDF file
CHC. A. Hoeffer
C. A. Hoeffer
ESE. Sanchez
E. Sanchez
RHR. J. Hagerman
R. J. Hagerman
YMY. Mu
Y. Mu
DND. V. Nguyen
D. V. Nguyen
FTFlora Tassone
Flora Tassone
Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and autism. The protein (FMRP) encoded by the fragile X mental retardation gene (FMR1), is an RNA‐binding protein linked to translational control. Recently, in the Fmr1 knockout mouse model of FXS, dysregulated translation initiation signaling was observed. To investigate whether an altered signaling was also a feature of subjects with FXS compared to typical developing controls, we isolated total RNA and translational control proteins from lymphocytes of subjects from both groups (38 FXS and 14 TD). Although we did not observe any difference in the expression level of messenger RNAs (mRNAs) for translational initiation control proteins isolated from participant with FXS, we found increased phosphorylation of the mammalian target of rapamycin (mTOR) substrate, p70 ribosomal subunit 6 kinase1 (S6K1) and of the mTOR regulator, the serine/threonine protein kinase (Akt), in their protein lysates. In addition, we observed increased phosphorylation of the cap binding protein eukaryotic initiation factor 4E (eIF4E) suggesting that protein synthesis is upregulated in FXS. Similar to the findings in lymphocytes, we observed increased phosphorylation of S6K1 in brain tissue from patients with FXS (n = 4) compared to normal age‐matched controls (n = 4). Finally, we detected increased expression of the cytoplasmic FMR1‐interacting protein 2 (CYFIP2), a known FMRP interactor. This data verify and extend previous findings using lymphocytes for studies of neuropsychiatric disorders and provide evidence that misregulation of mTOR signaling observed in the FXS mouse model also occurs in human FXS and may provide useful biomarkers for designing targeted treatments in FXS.

5 February 2007 in RNA
Verified
Journal Article
Closed access
PDF file
FTFlora Tassone
Flora Tassone
ABAlexandra Beilina
Alexandra Beilina
CCChiara Carosi
Chiara Carosi
SASerena Albertosi
Serena Albertosi
CBClaudia Bagni
Claudia Bagni
PHPaul J. Hagerman
Paul J. Hagerman
Carriers of premutation alleles (55–200 CGG repeats) of the fragile X mental retardation 1 (FMR1) gene have levels ofFMR1mRNA that are elevated by as much as 10-fold in peripheral blood leukocytes and CNS tissue. The excess expanded-repeat mRNA, per se, is now believed to result in forms of clinical involvement that are largely restricted to premutation carriers, including the neurodegenerative disorder, fragile X-associated tremor/ataxia syndrome (FXTAS). Although evidence to date suggests that the elevated mRNA is not due to increased stability, the basis for the increase is not known. In the current study, we have determined the relative transcriptional activities of premutation and normalFMR1alleles using a highly sensitive nuclear run-on assay that involves immunocapture of digoxigenin-modified run-on transcripts followed by PCR amplification of the nascent transcripts. Using the nuclear run-on approach, we demonstrate that the rate of run-on synthesis ofFMR1transcripts is increased in premutation alleles. The current run-on assay should be broadly applicable to studies of other genes with promoters of weak to moderate strength. The fraction of cappedFMR1mRNA remains unaltered for premutation transcripts, indicating that elevated message levels are not due to premature escape from the cotranscriptional capping process. We also show that, in contrast to the situation with myotonic dystrophy, there is no net nuclear sequestration of premutationFMR1mRNA. Finally, we have demonstrated that AGG interruptions within the CGG repeat element do not influenceFMR1mRNA levels.

12 April 2012 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
CYCarolyn Yrigollen
Carolyn Yrigollen
BDBlythe Durbin-Johnson
Blythe Durbin-Johnson
LGLouise Gane
Louise Gane
DNDavid L. Nelson
David L. Nelson
RHRandi Hagerman
Randi Hagerman
FTFlora Tassone
Flora Tassone
Purpose: The ability to accurately predict the likelihood of expansion of the CGG repeats in the FMR1 gene to a full mutation is of critical importance for genetic counseling of women who are carriers of premutation alleles (55–200 CGG repeats) and who are weighing the risk of having a child with fragile X syndrome. The presence of AGG interruptions within the CGG repeat tract is thought to decrease the likelihood of expansion to a full mutation during transmission, thereby reducing risk, although their contribution has not been quantified. Methods: We retrospectively analyzed 267 premutation alleles for number and position of AGG interruptions, length of pure CGG repeats, and CGG repeat lengths present in the offspring of the maternal transmissions. In addition, we determined the haplotypes of four markers flanking the 5′-UTR locus in the premutation mothers. Results: We found that the presence of AGG interruptions significantly increased genetic stability, whereas specific haplotypes had a marginal association with transmission instability. Conclusion: The presence of AGG interruptions reduced the risk of transmission of a full mutation for all maternal (premutation) repeat lengths below ~100 CGG repeats, with a differential risk (0 vs. 2 AGG) exceeding 60% for alleles in the 70- to 80-CGG repeat range. Genet Med 2012:14(8):729–736

1 April 2004 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
FTFlora Tassone
Flora Tassone
RHR J Hagerman
R J Hagerman
DGD Garcia-Arocena
D Garcia-Arocena
EKE W Khandjian
E W Khandjian
CGC M Greco
C M Greco
PHP J Hagerman
P J Hagerman